Ibalizumab Biosimilar - Research Grade

Human

CD4

>1mg/ml

Human IgG4

Anti-CD4 (GK1.5) In Vivo Antibody - Low Endotoxin (ICH1042), Bulk Anti-Human CD4 (OKT-4) Antibody (ICH1166), Anti-Mouse CD4 (YTS191) In Vivo Antibody - Low Endotoxin (ICH1210), Anti-Rat CD4 (OX-38) In Vivo Antibody - Low Endotoxin (ICH1255), Clenoliximab Biosimilar - Research Grade (ICH5193), Cedelizumab Biosimilar - Research Grade (ICH5430), Keliximab Biosimilar - Research Grade (ICH5616), Priliximab Biosimilar - Research Grade (ICH5788), Semzuvolimab Biosimilar - Research Grade (ICH5851), Tregalizumab Biosimilar - Research Grade (ICH5942)

https://www.imgt.org/mAb-DB/

ICH3002

P01730

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ibalizumab, an anti-CD4 monoclonal antibody, supplied strictly for research use. It is built around the same human CD4 target that ibalizumab engages, and is offered as a human IgG4 format for in-vitro and preclinical work rather than as the clinical drug. Researchers use analogs of this kind as well-characterised binding reagents and positive/isotype-matched controls in CD4 biology, in assays probing receptor engagement, epitope competition, and post-attachment mechanisms, and as tool molecules in antibody-engineering and ADCC/ADC-development pipelines. It is not intended for human or veterinary use. Material is available at research grade with low endotoxin (typically less than 1 EU/mg) and, where offered, an ultra-low endotoxin option (less than 0.5 EU/mg) suitable for sensitive cell-based and in-vivo standard applications. Bulk quantities in the milligram-to-gram range support assay development, screening campaigns, and reproducible lot-to-lot use across a research program, giving a cost-effective alternative to clinical-grade material for laboratory studies. CD4 (UniProt P01730) is a single-pass type I transmembrane glycoprotein of the immunoglobulin superfamily with four extracellular domains (D1-D4). It is expressed on helper T lymphocytes, and at lower levels on monocytes, macrophages, and dendritic cells. As a co-receptor for the T-cell receptor, CD4 binds the non-polymorphic region of MHC class II molecules on antigen-presenting cells, stabilising the immunological synapse and recruiting the Src-family kinase Lck via its cytoplasmic tail to initiate downstream signalling. CD4 is central to T-helper differentiation and adaptive immune coordination. It is also the primary cellular entry receptor for HIV-1: the viral gp120 envelope binds domain 1 of CD4, triggering conformational changes that expose co-receptor (CCR5/CXCR4) binding sites. Ibalizumab binds domain 2, allowing normal immune function while blocking post-attachment viral entry.

CD4, CD4mut, CD4 molecule, OKT4D, IMD79

Detects human CD4. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ibalizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Ibalizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Ibalizumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ibalizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ibalizumab that binds human CD4.